Literature DB >> 18820406

Axonal guidance molecules and the failure of axonal regeneration in the adult mammalian spinal cord.

S Bolsover1, J Fabes, P N Anderson.   

Abstract

A wide variety of molecules are involved as attractive or repulsive guidance cues in the developing nervous system. Some of these molecules are also expressed in the CNS of adult mammals where, following injury, they may repel regenerating axons, inhibit axonal regrowth, or control the behaviour of other cells important for the development of the meningeal and glial scars or the immune response to injury. Ephrins, semaphorins, Slits, Netrins, bone morphogenetic proteins (BMPs) and Wnts are among the most likely molecules to be involved in limiting axonal regeneration in the injured spinal cord. The receptors for these molecules are not universally expressed by neurons but there is evidence that ephrins and semaphorins limit regeneration of particular classes of axon into spinal cord lesion sites. It is likely that other repulsive guidance cues will also differentially affect the regeneration of specific tracts within the spinal cord. In addition to direct effects on axonal regeneration, many axonal guidance molecules have effects on glial, meningeal or immune system cells which also modulate the responses of CNS tissue to injury.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18820406

Source DB:  PubMed          Journal:  Restor Neurol Neurosci        ISSN: 0922-6028            Impact factor:   2.406


  15 in total

1.  Eph/ephrin interactions modulate muscle satellite cell motility and patterning.

Authors:  Danny A Stark; Rowan M Karvas; Ashley L Siegel; D D W Cornelison
Journal:  Development       Date:  2011-11-09       Impact factor: 6.868

Review 2.  Gene therapy approaches to enhancing plasticity and regeneration after spinal cord injury.

Authors:  Steffen Franz; Norbert Weidner; Armin Blesch
Journal:  Exp Neurol       Date:  2011-01-31       Impact factor: 5.330

3.  Endostatin binds nerve growth factor and thereby inhibits neurite outgrowth and neuronal migration in-vitro.

Authors:  Abraham Al Ahmad; Boyeon Lee; Jonathan Stack; Christi Parham; Joel Campbell; Douglas Clarke; Andrzej Fertala; Gregory J Bix
Journal:  Brain Res       Date:  2010-09-21       Impact factor: 3.252

Review 4.  Guidance molecules in axon regeneration.

Authors:  Roman J Giger; Edmund R Hollis; Mark H Tuszynski
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-06-02       Impact factor: 10.005

5.  Dynamic Alterations of Retinal EphA5 Expression in Retinocollicular Map Plasticity.

Authors:  Qi Cheng; Mark D Graves; Sarah L Pallas
Journal:  Dev Neurobiol       Date:  2019-04-01       Impact factor: 3.964

6.  Promoting directional axon growth from neural progenitors grafted into the injured spinal cord.

Authors:  Joseph F Bonner; Armin Blesch; Birgit Neuhuber; Itzhak Fischer
Journal:  J Neurosci Res       Date:  2010-05-01       Impact factor: 4.164

Review 7.  Roles of channels and receptors in the growth cone during PNS axonal regeneration.

Authors:  Sangwoo Shim; Guo-li Ming
Journal:  Exp Neurol       Date:  2009-10-13       Impact factor: 5.330

8.  Cellular toxicity following application of adeno-associated viral vector-mediated RNA interference in the nervous system.

Authors:  Erich M Ehlert; Ruben Eggers; Simone P Niclou; Joost Verhaagen
Journal:  BMC Neurosci       Date:  2010-02-18       Impact factor: 3.288

9.  ErbB1 epidermal growth factor receptor is a valid target for reducing the effects of multiple inhibitors of axonal regeneration.

Authors:  Veronica H L Leinster; Mary T Joy; Raisa E Vuononvirta; Stephen R Bolsover; Patrick N Anderson
Journal:  Exp Neurol       Date:  2012-09-26       Impact factor: 5.330

10.  Cortical gene expression in spinal cord injury and repair: insight into the functional complexity of the neural regeneration program.

Authors:  Fabian Kruse; Frank Bosse; Christina F Vogelaar; Nicole Brazda; Patrick Küry; Marcia Gasis; Hans W Müller
Journal:  Front Mol Neurosci       Date:  2011-09-29       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.